Company Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
The company was founded in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Jay Short |
Contact Details
Address: 11085 Torreyana Road San Diego, California 92121 United States | |
| Phone | 858 558 0708 |
| Website | bioatla.com |
Stock Details
| Ticker Symbol | BCAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001826892 |
| CUSIP Number | 09077B104 |
| ISIN Number | US09077B1044 |
| Employer ID | 85-1922320 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Richard A. Waldron | Senior Vice President and Chief Financial Officer |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Susie Melody | Senior Vice President of Human Resources |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research and Development |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Monica Sullivan | Senior Vice President of Intellectual Property and Contracts |
| Sheri Lydick | Chief Commercial Officer |
| Lisa M. Pelton | Accounting Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |